Baseline surveillance profile of doripenem against key Gram-negative pathogens encountered in Europe
Abstract number: 1733_1160
Aranza M.K., Draghi D.C., Jones M.E., Thornsberry C., Sahm D.F.
Background: DOR, is an investigational parenteral broad-spectrum 1-b-methyl carbapenem that is refractory to hydrolysis by most Gram-negative b-lactamases. It is under clinical development for complicated urinary tract infections, complicated intra-abdominal infections, and hospital acquired pneumonia (including ventilator-associated pneumonia). As a key component of the development programme, this surveillance initiative was done to establish baseline data on DOR activity against recent Gram-negative pathogens relative to other key b-lactam agents.
Methods: During 20052006, Citrobacter spp. (CP; n = 387), E. cloacae (EA; n = 406), E. coli (EC;n = 1213), K. pneumoniae (KP;n = 854), P. mirabilis (PM;n = 443), S. marcescens (SM; n = 291), P. aeruginosa (PA;n = 621), and Acinetobacter spp. (AC;n = 278) collected from 31 institutions in 12 European countries were centrally tested by broth microdilution (CLSI; M7-A6). Testing included DOR, imipenem (IMP), ceftazidime (CAZ), cefepime (FEP), piperacillin-tazobactam (PTZ) and other relevant agents.
Results: See the table.
Conclusions: Based on MIC90s, for every organism group surveyed, including PA, DOR's in vitro activity was comparable or more active than a carbapenem (IMP), the cephalosporins (CAZ, FEP), and a b-lactam (PTZ). These findings establish an important baseline for continued tracking of DOR activity as clinical development continues.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|